<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667446</url>
  </required_header>
  <id_info>
    <org_study_id>L-CP07-177</org_study_id>
    <nct_id>NCT00667446</nct_id>
  </id_info>
  <brief_title>Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty</brief_title>
  <official_title>A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30
      mg) is safe in treating children with Central Precocious Puberty over a longer period of time
      (36 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes a 36-month Study Drug Treatment Period (3-month treatment cycles), and a
      Safety Follow-up Period (12 weeks following the Month 36 visit). Participants will receive a
      total of twelve injections of the same treatment they received in the lead-in study,
      L-CP07-167 (NCT00635817) either leuprolide acetate 11.25 mg or 30 mg depot formulation. Each
      injection will be administered 3 months apart for up to 36 months of treatment. Study visits
      will occur on Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30 and 33 (1st through the 12th
      leuprolide acetate depot injections, respectively), Month 36, and 12 weeks later for the
      Safety Follow-up Visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone</measure>
    <time_frame>Day 1, Months 6, 12, 24, and 36</time_frame>
    <description>Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH &lt; 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)</measure>
    <time_frame>Day 1, Months 3, 6, 9, 12, and 24</time_frame>
    <description>The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol &lt; 20 pg/mL.
The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)</measure>
    <time_frame>Months 6, 9, 12, 24, 30, and 36</time_frame>
    <description>The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol &lt; 20 pg/mL.
The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Male Participants With Suppression of Basal Testosterone</measure>
    <time_frame>Day 1, Months 3, 6, 9, 12, 24, 30, and 36</time_frame>
    <description>The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone &lt; 30 ng/dL. Final visit is the participant's last visit closest to Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Peak-stimulated Luteinizing Hormone Concentration by Visit</measure>
    <time_frame>Baseline of the lead-in study L-CP07-167, Day 1, Months 6, 12, 24, and 36</time_frame>
    <description>Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)</measure>
    <time_frame>Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)</measure>
    <time_frame>Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
    <description>The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Growth Rate</measure>
    <time_frame>Baseline (the 1 year prior to the start of treatment in the lead-in study), and Day 1, Months 6, 12, 18, 24, 30, and 36</time_frame>
    <description>Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age</measure>
    <time_frame>Baseline (of the lead-in study L-CP07-167), and Day 1, Months 12, 24, and 36</time_frame>
    <description>Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula:
(BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Precocious</condition>
  <condition>Leuprolide Acetate</condition>
  <condition>Luteinizing Hormone (LH)</condition>
  <condition>Gonadotrophin-releasing Hormone Agonist (GnRHa)</condition>
  <condition>Tanner Staging</condition>
  <condition>Depot Formulation</condition>
  <condition>Suppression of LH</condition>
  <condition>Central Precocious Puberty (CPP)</condition>
  <condition>Gonadotrophin-releasing Hormone (GnRH)</condition>
  <condition>Lupron</condition>
  <condition>GnRH Analog</condition>
  <condition>Pediatrics Central Precocious Puberty</condition>
  <arm_group>
    <arm_group_label>Leuprolide Acetate 3M Depot 11.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprolide Acetate 3M Depot 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate 3 Month Depot</intervention_name>
    <arm_group_label>Leuprolide Acetate 3M Depot 11.25 mg</arm_group_label>
    <arm_group_label>Leuprolide Acetate 3M Depot 30 mg</arm_group_label>
    <other_name>ABT-818</other_name>
    <other_name>Lupron</other_name>
    <other_name>Leuprorelin acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed the Treatment Period of the lead-in study, L-CP07-167 (NCT00635817),
             and has documented luteinizing hormone suppression as evidenced by peak-stimulated
             luteinizing hormone &lt;4 mIU/mL at the Month 6 study visit of the lead-in study.

          -  Demonstrated suppression of the physical signs of puberty at Month 6 of the lead-in
             study.

          -  Subject is expected to receive at least 12 months of therapy to treat Central
             Precocious Puberty after study entry.

          -  In general good health with no uncontrolled, clinically significant disease which
             would interfere with bone maturation or mask the objectives of this protocol as
             assessed by the investigator.

        Exclusion Criteria:

          -  Incomplete precocious puberty, peripheral precocious puberty or evidence of any
             abnormal pituitary, hypothalamic, adrenal, thyroid and gonadal function (other than
             premature secretion of gonadotropins) not adequately controlled, unstable intracranial
             tumors except hamartoma.

          -  Bone age ≥14 years for girls and ≥15 years for boys (based on the Month 6 lead in
             study, L-CP07-167, radiographic results).

          -  Has an abnormal laboratory value suggesting a clinically significant underlying
             disease or condition.

          -  Chronic illness requiring treatment that may interfere with growth, ie, chronic
             steroid use, renal failure, moderate to severe scoliosis.

          -  Current therapy with medroxyprogesterone acetate.

          -  Current therapy with growth hormone.

          -  Current therapy with insulin-like growth factor-1 (IGF-1).

          -  Current use of an estrogen preparation.

          -  Any concomitant medical condition that, in the opinion of the investigator, may expose
             a subject to an unacceptable level of safety risk or that affects subject compliance.

          -  Subject has a positive pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bacher, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 13521</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14922</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26043</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 20802</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 22425</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 18181</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26364</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 26983</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 20821</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71130-3932</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 23643</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 23502</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14121</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 23802</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 13324</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 16506</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 14024</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 23182</name>
      <address>
        <city>Bayamon</city>
        <zip>00960</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 21721</name>
      <address>
        <city>Ponce</city>
        <zip>00717-2116</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 25908</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 23082</name>
      <address>
        <city>San Juan</city>
        <zip>00936-8344</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>October 16, 2013</results_first_submitted>
  <results_first_submitted_qc>October 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2013</results_first_posted>
  <last_update_submitted>January 8, 2014</last_update_submitted>
  <last_update_submitted_qc>January 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GnRH analog</keyword>
  <keyword>Luteinizing hormone (LH)</keyword>
  <keyword>Gonadotrophin-releasing hormone agonist(GnRHa)</keyword>
  <keyword>Suppression of LH</keyword>
  <keyword>Gonadotrophin-releasing hormone (GnRH)</keyword>
  <keyword>CPP</keyword>
  <keyword>Leuprolide acetate</keyword>
  <keyword>Central Precocious Puberty</keyword>
  <keyword>Depot formulation</keyword>
  <keyword>Lupron</keyword>
  <keyword>Tanner staging</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Puberty, Precocious</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants who successfully completed and showed maintenance of luteinizing hormone suppression through the 6-month treatment period of the lead-in study L-CP07-167 (NCT00635817) received the same treatment in this study that they were previously assigned in the lead-in study.</recruitment_details>
      <pre_assignment_details>At the end of the Treatment Period, participants who completed the study or prematurely discontinued from the study could enter the Safety Follow-Up Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
          <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart during the Treatment Period. During the Safety Follow-Up Period participants were offered standard of care treatment as deemed appropriate by the investigator.</description>
        </group>
        <group group_id="P2">
          <title>Leuprolide Acetate 3M Depot 30 mg</title>
          <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart during the Treatment Period. During the the Safety Follow-Up Period participants were offered standard of care treatment as deemed appropriate by the investigator.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period (36 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ready to enter puberty based on age</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Adequately Suppressed on Therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Therapeutic Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Safety Follow-up Period (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No Longer Needed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who received at least 1 dose of study drug in this extension study.</population>
      <group_list>
        <group group_id="B1">
          <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
          <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
        </group>
        <group group_id="B2">
          <title>Leuprolide Acetate 3M Depot 30 mg</title>
          <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.50" spread="1.71"/>
                    <measurement group_id="B2" value="8.45" spread="1.52"/>
                    <measurement group_id="B3" value="8.47" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone</title>
        <description>Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH &lt; 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Day 1, Months 6, 12, 24, and 36</time_frame>
        <population>Intention-to-treat, defined as patients who received at least 1 dose of study drug with at least 1 post-baseline measurement of any maintenance of suppression variable, &amp; did not prematurely discontinue in the 1st 30 days due to inadequate suppression at Month 6 of the lead-in study. N= the number of patients with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone</title>
          <description>Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH &lt; 4 mIU/mL. Peak-stimulated LH refers to the maximum LH concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Participants who failed suppression at previous visit and prematurely discontinued were counted as having failed future visits also. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat, defined as patients who received at least 1 dose of study drug with at least 1 post-baseline measurement of any maintenance of suppression variable, &amp; did not prematurely discontinue in the 1st 30 days due to inadequate suppression at Month 6 of the lead-in study. N= the number of patients with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N= 32, 37]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="83.78" upper_limit="99.92"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.51" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 [N=32, 36]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="79.19" upper_limit="99.23"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.26" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=31, 32]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="74.25" upper_limit="97.96"/>
                    <measurement group_id="O2" value="96.9" lower_limit="83.78" upper_limit="99.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=16, 18]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="64.65" upper_limit="98.45"/>
                    <measurement group_id="O2" value="100.0" lower_limit="81.47" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=9, 11]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="39.99" upper_limit="97.19"/>
                    <measurement group_id="O2" value="100.0" lower_limit="71.51" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=33, 36]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9" lower_limit="79.77" upper_limit="99.26"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.26" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)</title>
        <description>The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol &lt; 20 pg/mL.
The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Day 1, Months 3, 6, 9, 12, and 24</time_frame>
        <population>Intention-to-treat female population. N = the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)</title>
          <description>The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol &lt; 20 pg/mL.
The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed before this change occurred, with an LLOQ of 1 pg/mL. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat female population. N = the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N=28, 30]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="81.65" upper_limit="99.91"/>
                    <measurement group_id="O2" value="100.0" lower_limit="88.43" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 [N=29, 33]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="88.06" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.42" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 [N=26, 25]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="86.77" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="86.28" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 [N=18, 18]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="81.47" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="81.47" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=10, 12]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="69.15" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="73.54" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=1, 0]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.50" upper_limit="100.00"/>
                    <measurement group_id="O2" value="NA">No participants with available data at this time point</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=31, 33]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="88.78" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.42" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)</title>
        <description>The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol &lt; 20 pg/mL.
The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Months 6, 9, 12, 24, 30, and 36</time_frame>
        <population>Intention-to-treat female population. N = the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)</title>
          <description>The percentage of female participants with suppression of basal estradiol to prepubertal levels, defined as estradiol &lt; 20 pg/mL.
The estradiol assay was changed in June of 2010, and the lower limit of quantitation (LLOQ) was increased from 1 pg/mL to 10 pg/mL. This outcome measure reports data for assays performed after this change occurred, with an LLOQ of 10 pg/mL. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat female population. N = the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 [N=4, 6]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.76" upper_limit="100.00"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.88" upper_limit="99.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 [N=13, 10]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="31.58" upper_limit="86.14"/>
                    <measurement group_id="O2" value="40.0" lower_limit="12.16" upper_limit="73.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=20, 15]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" lower_limit="23.06" upper_limit="68.47"/>
                    <measurement group_id="O2" value="60.0" lower_limit="32.29" upper_limit="83.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=14, 15]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="23.04" upper_limit="76.96"/>
                    <measurement group_id="O2" value="53.3" lower_limit="26.59" upper_limit="78.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 [N=9, 15]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="7.49" upper_limit="70.07"/>
                    <measurement group_id="O2" value="26.7" lower_limit="7.79" upper_limit="55.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=7, 11]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" lower_limit="3.67" upper_limit="70.96"/>
                    <measurement group_id="O2" value="36.4" lower_limit="10.93" upper_limit="69.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=24, 26]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" lower_limit="12.62" upper_limit="51.09"/>
                    <measurement group_id="O2" value="30.8" lower_limit="14.33" upper_limit="51.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Male Participants With Suppression of Basal Testosterone</title>
        <description>The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone &lt; 30 ng/dL. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Day 1, Months 3, 6, 9, 12, 24, 30, and 36</time_frame>
        <population>Intention-to-treat male population. N = the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Male Participants With Suppression of Basal Testosterone</title>
          <description>The percentage of male participants with suppression of basal testosterone to prepubertal levels, defined as testosterone &lt; 30 ng/dL. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat male population. N = the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N= 2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.82" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.82" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O2" value="80.0" lower_limit="28.36" upper_limit="99.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O2" value="80.0" lower_limit="28.36" upper_limit="99.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=1, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.50" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.82" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=1, 3]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.50" upper_limit="100.00"/>
                    <measurement group_id="O2" value="66.7" lower_limit="9.43" upper_limit="99.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 [N=0, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with available data at this time point</measurement>
                    <measurement group_id="O2" value="100.0" lower_limit="2.50" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=0, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with available data at this time point</measurement>
                    <measurement group_id="O2" value="100.0" lower_limit="2.50" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.81" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.82" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Peak-stimulated Luteinizing Hormone Concentration by Visit</title>
        <description>Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Baseline of the lead-in study L-CP07-167, Day 1, Months 6, 12, 24, and 36</time_frame>
        <population>Intention-to-treat. N = the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Peak-stimulated Luteinizing Hormone Concentration by Visit</title>
          <description>Peak-stimulated luteinizing hormone refers to the maximum luteinizing hormone concentration measured 30 and 60 minutes after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat. N = the number of participants with available data at each time point.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=33, 38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.89" spread="38.46"/>
                    <measurement group_id="O2" value="10.16" spread="12.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 [N=32, 37]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.03"/>
                    <measurement group_id="O2" value="1.49" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 [N=32, 36]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.16"/>
                    <measurement group_id="O2" value="1.62" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=31, 32]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="1.20"/>
                    <measurement group_id="O2" value="1.58" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=14, 18]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="0.97"/>
                    <measurement group_id="O2" value="0.88" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=7, 11]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.85"/>
                    <measurement group_id="O2" value="0.91" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=33, 36]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="1.13"/>
                    <measurement group_id="O2" value="1.15" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)</title>
        <description>The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Intention-to-treat female population, excluding participants who entered the study at Stage 5. N = the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)</title>
          <description>The percentage of female participants with suppression of breast development. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression of breast development is defined as regression or no progression of breast development from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat female population, excluding participants who entered the study at Stage 5. N = the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N= 31, 31]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="74.2" upper_limit="98.0"/>
                    <measurement group_id="O2" value="83.9" lower_limit="66.3" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 [N=29, 31]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="68.3" upper_limit="96.1"/>
                    <measurement group_id="O2" value="87.1" lower_limit="70.2" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 [N=31, 30]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" lower_limit="74.2" upper_limit="98.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="61.4" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 [N=31, 28]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="70.2" upper_limit="96.4"/>
                    <measurement group_id="O2" value="75.0" lower_limit="55.1" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=28, 26]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O2" value="80.8" lower_limit="60.6" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 [N=17, 20]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.4" lower_limit="56.6" upper_limit="96.2"/>
                    <measurement group_id="O2" value="75.0" lower_limit="50.9" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=14, 16]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" lower_limit="49.2" upper_limit="95.3"/>
                    <measurement group_id="O2" value="75.0" lower_limit="47.6" upper_limit="92.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 [N=10, 16]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="68.8" lower_limit="41.3" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=8, 12]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="47.3" upper_limit="99.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="34.9" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=31, 31]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" lower_limit="66.3" upper_limit="94.5"/>
                    <measurement group_id="O2" value="71.0" lower_limit="52.0" upper_limit="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)</title>
        <description>The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.</description>
        <time_frame>Baseline (of the lead-in study L-CP07-167), Day 1, Months 3, 6, 9, 12, 18, 24, 30, and 36</time_frame>
        <population>Intention-to-treat male population, excluding participants who entered the study at Stage 5. N = the number of participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)</title>
          <description>The percentage of male participants with suppression of testicular volume and genital staging. Testicular volume was calculated from the length, width and height of each testicle measured by ultrasound. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a modified Tanner Staging pictogram. Suppression is defined as regression or no progression in both testicular volume and genital staging from Baseline (of the lead-in study L-CP07-167) according to pubertal staging. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Final visit is the participant's last visit closest to Month 36.</description>
          <population>Intention-to-treat male population, excluding participants who entered the study at Stage 5. N = the number of participants with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N= 2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="40.0" lower_limit="5.3" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6 [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9 [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="40.0" lower_limit="5.3" upper_limit="85.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=1, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 [N=1, 3]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=1, 3]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 [N=1, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=0, 1]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with available data at this time point</measurement>
                    <measurement group_id="O2" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=2, 5]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="20.0" lower_limit="0.5" upper_limit="71.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Growth Rate</title>
        <description>Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.</description>
        <time_frame>Baseline (the 1 year prior to the start of treatment in the lead-in study), and Day 1, Months 6, 12, 18, 24, 30, and 36</time_frame>
        <population>Intention-to-treat with available growth rate data. N = participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Growth Rate</title>
          <description>Baseline growth rate was the growth rate in the one year prior to Day 1 of the lead-in study L-CP07-167. Growth rates were calculated as the ratio of the change in height to the change in chronological age with an approximate 6-month interval for Day 1, Months 6, 12, 18, 24, 30, 36 and the Final Treatment Visit.</description>
          <population>Intention-to-treat with available growth rate data. N = participants with available data at each time point.</population>
          <units>cm/year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline [N=32, 38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="3.96"/>
                    <measurement group_id="O2" value="7.53" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Day 1 [N=32, 38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.67" spread="3.90"/>
                    <measurement group_id="O2" value="-1.65" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 6 [N=32, 37]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="3.78"/>
                    <measurement group_id="O2" value="-2.04" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 12 [N=28, 32]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="3.90"/>
                    <measurement group_id="O2" value="-2.28" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 18 [N=18, 23]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="4.29"/>
                    <measurement group_id="O2" value="-2.06" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 24 [N=15, 19]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="4.85"/>
                    <measurement group_id="O2" value="-1.59" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 30 [N=11, 17]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.86" spread="5.45"/>
                    <measurement group_id="O2" value="-2.13" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 36 [N=8, 13]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="5.93"/>
                    <measurement group_id="O2" value="-2.19" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Final Visit [N=32, 38]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="3.78"/>
                    <measurement group_id="O2" value="-2.64" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age</title>
        <description>Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula:
(BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).</description>
        <time_frame>Baseline (of the lead-in study L-CP07-167), and Day 1, Months 12, 24, and 36</time_frame>
        <population>Intention-to-treat with available bone age data. N = participants with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
          </group>
          <group group_id="O2">
            <title>Leuprolide Acetate 3M Depot 30 mg</title>
            <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age</title>
          <description>Bone age was determined by left hand/wrist bone age radiographs that were evaluated using the Fels Method by a central reader. The ratio of change from Baseline in bone age (BA)/change from Baseline in chronological age (CA) was calculated using the following formula:
(BA at Post-baseline Treatment Visit - BA at Baseline) / (CA at Post-baseline Treatment Visit - CA at Baseline).</description>
          <population>Intention-to-treat with available bone age data. N = participants with available data at each time point.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 [N=32, 37]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.56"/>
                    <measurement group_id="O2" value="1.02" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 [N=32, 32]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.33"/>
                    <measurement group_id="O2" value="0.62" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 [N=14, 17]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.30"/>
                    <measurement group_id="O2" value="0.72" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 [N=5, 11]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.15"/>
                    <measurement group_id="O2" value="0.64" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit [N=33, 32]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.28"/>
                    <measurement group_id="O2" value="0.56" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>37 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Leuprolide Acetate 3M Depot 11.25 mg</title>
          <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months apart.</description>
        </group>
        <group group_id="E2">
          <title>Leuprolide Acetate 3M Depot 30 mg</title>
          <description>Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>INTRACRANIAL PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>MYOPIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BODY TINEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>RASH PAPULAR</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie, (prior sponsor, Abbott)</organization>
      <phone>800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

